David Bai, PharmD


MRD Can't Predict Response in Early Days of Intensive AML Therapy, Study Says

February 09, 2019

Molecular minimal residual disease (MRD) testing during the first 4 days of induction therapy does not differentiate responders and nonresponders and should not be used in predicting clinical response for patients with acute myeloid leukemia (AML), according to the results from a recent study.

Ineligibility for Intensive Chemotherapy Impacts QoL Scores, Survival in AML

February 07, 2019

Patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy tend to have poor health-related quality of life (HRQoL) scores that are independent predictors of poor survival, a recent study reported.

Long Noncoding RNAs Contribute to Prominent Signaling Pathways in BCP-ALL

February 02, 2019

Long noncoding RNAs (lncRNAs) are involved in the pathogenesis of b-cell precursor acute lymphoblastic leukemia (BCP-ALL) and contribute to the stratification of BCP-ALL subtypes, according to results from a recent study.